DZ1958A1 - Composés inhibiteurs de l'enzyme l-lpa compositionpharmaceutiques les composant et procédés pour leur préparation. - Google Patents

Composés inhibiteurs de l'enzyme l-lpa compositionpharmaceutiques les composant et procédés pour leur préparation.

Info

Publication number
DZ1958A1
DZ1958A1 DZ950141A DZ950141A DZ1958A1 DZ 1958 A1 DZ1958 A1 DZ 1958A1 DZ 950141 A DZ950141 A DZ 950141A DZ 950141 A DZ950141 A DZ 950141A DZ 1958 A1 DZ1958 A1 DZ 1958A1
Authority
DZ
Algeria
Prior art keywords
lpa
enzyme
preparation
methods
pharmaceutical compositions
Prior art date
Application number
DZ950141A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9426020.5A external-priority patent/GB9426020D0/en
Priority claimed from GBGB9426030.4A external-priority patent/GB9426030D0/en
Priority claimed from GBGB9511599.4A external-priority patent/GB9511599D0/en
Priority claimed from GBGB9511600.0A external-priority patent/GB9511600D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DZ1958A1 publication Critical patent/DZ1958A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DZ950141A 1994-12-22 1995-12-20 Composés inhibiteurs de l'enzyme l-lpa compositionpharmaceutiques les composant et procédés pour leur préparation. DZ1958A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9426020.5A GB9426020D0 (en) 1994-12-22 1994-12-22 Novel compounds
GBGB9426030.4A GB9426030D0 (en) 1994-12-23 1994-12-23 Novel compounds
GBGB9511599.4A GB9511599D0 (en) 1995-06-08 1995-06-08 Novel compounds
GBGB9511600.0A GB9511600D0 (en) 1995-06-08 1995-06-08 Novel compounds

Publications (1)

Publication Number Publication Date
DZ1958A1 true DZ1958A1 (fr) 2002-02-17

Family

ID=27451242

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ950141A DZ1958A1 (fr) 1994-12-22 1995-12-20 Composés inhibiteurs de l'enzyme l-lpa compositionpharmaceutiques les composant et procédés pour leur préparation.

Country Status (24)

Country Link
US (1) US5990102A (fr)
EP (1) EP0799200A1 (fr)
JP (1) JPH11500415A (fr)
CN (1) CN1175246A (fr)
AP (1) AP9701007A0 (fr)
AR (1) AR002012A1 (fr)
AU (1) AU704407B2 (fr)
BG (1) BG101687A (fr)
BR (1) BR9510420A (fr)
CA (1) CA2208530A1 (fr)
CZ (1) CZ192297A3 (fr)
DZ (1) DZ1958A1 (fr)
FI (1) FI972584A (fr)
HU (1) HUT77089A (fr)
IL (1) IL116485A0 (fr)
MA (1) MA23834A1 (fr)
MX (1) MX9704736A (fr)
NO (1) NO972909L (fr)
NZ (1) NZ298416A (fr)
OA (1) OA10737A (fr)
PL (1) PL320937A1 (fr)
SK (1) SK80397A3 (fr)
TR (1) TR199501655A2 (fr)
WO (1) WO1996019451A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ422197A3 (cs) * 1995-07-01 1998-06-17 Smithkline Beecham Plc Azetidinonové deriváty, způsob jejich přípravy, meziprodukty tohoto postupu, farmaceutický prostředek obsahující tyto sloučeniny a použití těchto sloučenin jako léčiv
EP0865429A1 (fr) * 1995-12-08 1998-09-23 Smithkline Beecham Plc Composes azetidinone destines au traitement de l'atherosclerose
WO1997021675A1 (fr) * 1995-12-08 1997-06-19 Smithkline Beecham Plc Derives de beta-lactame monocycliques utilises dans le traitement de l'atherosclerose
GB9608649D0 (en) * 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
PL329530A1 (en) * 1996-04-26 1999-03-29 Smithkline Beecham Plc Derivatives of azetidinone for use in treatment of arterial atheromatosis
WO2000005204A1 (fr) * 1998-07-23 2000-02-03 Shionogi & Co., Ltd. COMPOSES DE β-LACTAME MONOCYCLIQUES ET INHIBITEURS DE LA CHYMASE LES RENFERMANT
ATE333446T1 (de) 2000-02-16 2006-08-15 Smithkline Beecham Plc Pyrimidin-4-onderivat als ldl-pla2 inhibitor
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
CN1756755A (zh) * 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081002A1 (fr) 2003-03-07 2004-09-23 Schering Corporation Composes d'azetidinone substitues, leurs formulations et utilisations en vue du traitement de l'hypercholesterolemie
CA2565387A1 (fr) * 2004-05-03 2005-11-17 Ilypsa, Inc. Modulation de la lysophosphatidylcholine et traitement des etats induits par un regime alimentaire
EA018101B1 (ru) 2007-05-11 2013-05-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способы лечения кожных язв
KR101690390B1 (ko) 2007-05-11 2016-12-27 토마스 제퍼슨 유니버시티 신경변성 질환 및 장애의 치료 및 예방 방법
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
AU2011340690C1 (en) 2010-12-06 2016-03-10 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp - PLA2
EP2651403B1 (fr) 2010-12-17 2020-12-02 Glaxo Group Limited Procédés de traitement et de prévention de maladies oculaires
US20140171431A1 (en) 2011-06-27 2014-06-19 Jianhua Shen Azole heterocyclic compound, preparation method, pharmaceutical composition and use
US8975400B2 (en) 2011-07-27 2015-03-10 Glaxo Group Limited 2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors
WO2013014185A1 (fr) 2011-07-27 2013-01-31 Glaxo Group Limited Composés pyrimidones bicycliques
CN105008365B (zh) 2013-01-25 2017-03-15 葛兰素史密斯克莱知识产权发展有限公司 化合物
EP2948452B1 (fr) 2013-01-25 2017-08-09 GlaxoSmithKline Intellectual Property Development Limited Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one
KR20150108896A (ko) 2013-01-25 2015-09-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Lp-pla2의 억제제로서의 비시클릭 피리미돈 화합물
WO2015179293A1 (fr) * 2014-05-18 2015-11-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activateurs et inhibiteurs de petites molécules de lécithine-cholestérol acyltransférase
WO2016012917A1 (fr) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
WO2016012916A1 (fr) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
WO2021089032A1 (fr) 2019-11-09 2021-05-14 上海赛默罗生物科技有限公司 Dérivé de dihydroimidazopyrimidone tricyclique, son procédé de préparation, composition pharmaceutique et son utilisation
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5559193A (en) * 1978-09-20 1980-05-02 Glaxo Group Ltd Bblactam compound
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
AP9701007A0 (en) 1997-07-31
CN1175246A (zh) 1998-03-04
CA2208530A1 (fr) 1996-06-27
EP0799200A1 (fr) 1997-10-08
CZ192297A3 (en) 1997-11-12
MX9704736A (es) 1997-10-31
NZ298416A (en) 1999-03-29
SK80397A3 (en) 1998-01-14
WO1996019451A1 (fr) 1996-06-27
NO972909D0 (no) 1997-06-20
AR002012A1 (es) 1998-01-07
AU704407B2 (en) 1999-04-22
OA10737A (en) 2002-12-10
TR199501655A2 (tr) 1996-07-21
PL320937A1 (en) 1997-11-10
BG101687A (en) 1998-02-27
US5990102A (en) 1999-11-23
MA23834A1 (fr) 1996-10-01
FI972584A0 (fi) 1997-06-17
JPH11500415A (ja) 1999-01-12
HUT77089A (hu) 1998-03-02
FI972584A (fi) 1997-08-19
NO972909L (no) 1997-08-20
IL116485A0 (en) 1996-08-04
BR9510420A (pt) 2004-04-20
AU4389896A (en) 1996-07-10

Similar Documents

Publication Publication Date Title
DZ1958A1 (fr) Composés inhibiteurs de l'enzyme l-lpa compositionpharmaceutiques les composant et procédés pour leur préparation.
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2745A1 (fr) BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2300A1 (fr) Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr) Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2321A1 (fr) Aralkyl-et arylkylidène-lactames et -imides hétér ocycliques procédés pour leur préparation et compositions pharamceutiques les contenant.
DZ2889A1 (fr) 4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant.
MA26536A1 (fr) Association de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation.
DZ2358A1 (fr) Amides inhibiteurs de sécrétion de apo b/mtp procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2416A1 (fr) Dérivés d'acide arylsulfonylhydroxamique procédé pour leur préparation et compositions les contenant.
DZ2465A1 (fr) Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions les contenant.
DZ2217A1 (fr) Dérivés d'imidazole substitués, procédé pour leur préparation et compositions les contenant.
DZ2303A1 (fr) Dérivés d'indazole nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
CY2537B1 (fr) Composés hétérocycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2197A1 (fr) Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2360A1 (fr) Dérivés de pyrazole procédé pour leur préparation et compositions les contenant
DZ2753A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tétrahydropyranne-4-carboxyliques) procédé pour leur préparation et compositions les contenant.
DZ1889A1 (fr) Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2188A1 (fr) Dérivés de quinoxalinedone, procédés et intermédiaires pour leur préparation et compositions pharmaceutiques les contenant.
DZ2407A1 (fr) Dérivés de sulfonylurée procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2045A1 (fr) Amides thérapeutiques, procédé pour leur préparation et compositions les contenant.
MA26526A1 (fr) Derives d'indole inhibiteurs de cyclo-oxygenase, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2740136B1 (fr) Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
DZ2394A1 (fr) Dérivés de quinoléine et dérivés de quinazoline nouveax procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2414A1 (fr) 2-amino-6-(2-substitué-4-phenoxy)substituté-pyridines procédé pour leur préparation et compositions pharmaceutiques les contenant.